S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
pixel
Log in
NASDAQ:ACAD

ACADIA Pharmaceuticals Competitors

$47.44
+0.50 (+1.07 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$45.55
Now: $47.44
$48.10
50-Day Range
$46.58
MA: $50.84
$54.46
52-Week Range
$30.02
Now: $47.44
$58.72
Volume1.61 million shs
Average Volume916,090 shs
Market Capitalization$7.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.44

Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) Vs. BGNE, GMAB, HZNP, CTLT, RPRX, and ALNY

Should you be buying ACAD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ACADIA Pharmaceuticals, including BeiGene (BGNE), Genmab A/S (GMAB), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Royalty Pharma (RPRX), and Alnylam Pharmaceuticals (ALNY).

ACADIA Pharmaceuticals (NASDAQ:ACAD) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Risk and Volatility

ACADIA Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Earnings and Valuation

This table compares ACADIA Pharmaceuticals and BeiGene's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million22.39$-235,260,000.00($1.60)-29.65
BeiGene$428.21 million65.06$-948,630,000.00($15.80)-19.28

ACADIA Pharmaceuticals has higher earnings, but lower revenue than BeiGene. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of BeiGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ACADIA Pharmaceuticals and BeiGene, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals011413.00
BeiGene22402.25

ACADIA Pharmaceuticals presently has a consensus price target of $62.2667, indicating a potential upside of 31.25%. BeiGene has a consensus price target of $310.00, indicating a potential upside of 1.79%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than BeiGene.

Profitability

This table compares ACADIA Pharmaceuticals and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%
BeiGene-569.22%-56.81%-39.93%

Summary

ACADIA Pharmaceuticals beats BeiGene on 12 of the 15 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Risk and Volatility

ACADIA Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Earnings and Valuation

This table compares ACADIA Pharmaceuticals and Genmab A/S's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million22.39$-235,260,000.00($1.60)-29.65
Genmab A/S$804.57 million26.52$324.68 million$0.5163.82

Genmab A/S has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.2% of Genmab A/S shares are owned by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ACADIA Pharmaceuticals and Genmab A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals011413.00
Genmab A/S34702.29

ACADIA Pharmaceuticals presently has a consensus price target of $62.2667, indicating a potential upside of 31.25%. Genmab A/S has a consensus price target of $42.1429, indicating a potential upside of 29.47%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Genmab A/S.

Profitability

This table compares ACADIA Pharmaceuticals and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%
Genmab A/S50.99%34.40%30.67%

Summary

Genmab A/S beats ACADIA Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Risk and Volatility

ACADIA Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Insider & Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ACADIA Pharmaceuticals and Horizon Therapeutics Public, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals011413.00
Horizon Therapeutics Public00803.00

ACADIA Pharmaceuticals presently has a consensus price target of $62.2667, indicating a potential upside of 31.25%. Horizon Therapeutics Public has a consensus price target of $101.8889, indicating a potential upside of 11.95%. Given ACADIA Pharmaceuticals' higher probable upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Horizon Therapeutics Public.

Profitability

This table compares ACADIA Pharmaceuticals and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%
Horizon Therapeutics Public43.55%25.66%14.19%

Earnings and Valuation

This table compares ACADIA Pharmaceuticals and Horizon Therapeutics Public's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million22.39$-235,260,000.00($1.60)-29.65
Horizon Therapeutics Public$1.30 billion15.68$573.02 million$1.9446.91

Horizon Therapeutics Public has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Catalent (NYSE:CTLT) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Volatility & Risk

Catalent has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Insider & Institutional Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. 1.0% of Catalent shares are owned by company insiders. Comparatively, 27.7% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Catalent and ACADIA Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
ACADIA Pharmaceuticals011413.00

Catalent currently has a consensus target price of $125.1250, indicating a potential upside of 15.46%. ACADIA Pharmaceuticals has a consensus target price of $62.2667, indicating a potential upside of 31.25%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Catalent.

Profitability

This table compares Catalent and ACADIA Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%

Earnings & Valuation

This table compares Catalent and ACADIA Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion5.96$173 million$1.8857.64
ACADIA Pharmaceuticals$339.08 million22.39$-235,260,000.00($1.60)-29.65

Catalent has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Summary

Catalent beats ACADIA Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are owned by institutional investors. Comparatively, 93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. 2.5% of Royalty Pharma shares are owned by company insiders. Comparatively, 27.7% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Royalty Pharma and ACADIA Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
ACADIA Pharmaceuticals011413.00

Royalty Pharma currently has a consensus target price of $51.8750, indicating a potential upside of 19.06%. ACADIA Pharmaceuticals has a consensus target price of $62.2667, indicating a potential upside of 31.25%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Royalty Pharma.

Profitability

This table compares Royalty Pharma and ACADIA Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%

Earnings & Valuation

This table compares Royalty Pharma and ACADIA Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
ACADIA Pharmaceuticals$339.08 million22.39$-235,260,000.00($1.60)-29.65

Royalty Pharma has higher earnings, but lower revenue than ACADIA Pharmaceuticals.

Summary

ACADIA Pharmaceuticals beats Royalty Pharma on 7 of the 10 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Volatility & Risk

Alnylam Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Insider & Institutional Ownership

92.4% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 27.7% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Alnylam Pharmaceuticals and ACADIA Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alnylam Pharmaceuticals19902.42
ACADIA Pharmaceuticals011413.00

Alnylam Pharmaceuticals currently has a consensus target price of $163.4211, indicating a potential upside of 13.24%. ACADIA Pharmaceuticals has a consensus target price of $62.2667, indicating a potential upside of 31.25%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.

Profitability

This table compares Alnylam Pharmaceuticals and ACADIA Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%

Earnings & Valuation

This table compares Alnylam Pharmaceuticals and ACADIA Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$219.75 million76.84$-886,120,000.00($8.11)-17.80
ACADIA Pharmaceuticals$339.08 million22.39$-235,260,000.00($1.60)-29.65

ACADIA Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

ACADIA Pharmaceuticals beats Alnylam Pharmaceuticals on 11 of the 15 factors compared between the two stocks.


ACADIA Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BeiGene logo
BGNE
BeiGene
1.1$304.55+0.6%$27.86 billion$428.21 million-15.07Earnings Announcement
Analyst Downgrade
Analyst Revision
Genmab A/S logo
GMAB
Genmab A/S
1.7$32.55+3.9%$21.34 billion$804.57 million25.23Analyst Report
Increase in Short Interest
Analyst Revision
Gap Up
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.01+3.8%$20.39 billion$1.30 billion24.87
Catalent logo
CTLT
Catalent
1.9$108.37+5.0%$18.45 billion$3.09 billion69.03Analyst Report
Royalty Pharma logo
RPRX
Royalty Pharma
1.6$43.57+7.8%$16.91 billionN/A0.00
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$144.32+5.6%$16.89 billion$219.75 million-18.43Analyst Report
CureVac logo
CVAC
CureVac
0.6$83.56+11.1%$15.62 billionN/A0.00Decrease in Short Interest
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$30.87+4.8%$14.57 billion$3.07 billion-54.16Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$76.09+2.4%$13.84 billion$1.70 billion17.41Earnings Announcement
Analyst Report
Analyst Revision
Zai Lab logo
ZLAB
Zai Lab
1.4$140.67+5.2%$12.38 billion$12.98 million-46.43Analyst Revision
News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.92+1.7%$11.93 billion$16.89 billion-2.97
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$32.56+0.9%$11.56 billion$8.60 billion-5.97Analyst Report
Analyst Revision
Grifols logo
GRFS
Grifols
1.2$16.00+1.0%$11.00 billion$5.71 billion14.29Analyst Report
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$60.93+0.8%$10.13 billion$2.32 billion50.36
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$188.90+7.1%$9.56 billion$3.34 million-24.53Earnings Announcement
Analyst Report
Analyst Revision
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
1.6$63.90+3.6%$9.52 billion$40.56 million-18.74Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$162.91+1.7%$9.18 billion$2.16 billion51.39Analyst Report
Increase in Short Interest
Analyst Revision
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.2$125.30+11.7%$8.39 billion$103.71 million-28.54Analyst Report
Insider Selling
News Coverage
Gap Up
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.3$152.90+1.5%$8.17 billion$14.98 million-18.62
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$75.48+6.8%$7.83 billion$87.99 million-89.86
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$52.82+4.7%$7.44 billion$1.12 billion110.04Analyst Upgrade
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.9$163.21+2.1%$7.27 billion$1.45 billion15.44Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.3$99.14+7.7%$6.89 billion$85.54 million0.00
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$87.11+2.1%$6.87 billion$380.83 million-11.14Earnings Announcement
Analyst Report
Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$214.76+0.1%$6.67 billion$311.33 million-124.86Decrease in Short Interest
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$36.34+3.5%$6.13 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Allakos logo
ALLK
Allakos
1.7$111.38+4.2%$5.85 billionN/A-40.65Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
AVIR
Atea Pharmaceuticals
1.7$70.61+1.7%$5.83 billionN/A0.00Upcoming Earnings
Decrease in Short Interest
Gap Down
Perrigo logo
PRGO
Perrigo
2.6$41.28+2.0%$5.63 billion$4.84 billion-687.89Earnings Announcement
Analyst Revision
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$42.73+5.0%$5.62 billion$150,000.00-20.16Earnings Announcement
Analyst Revision
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.02+6.2%$5.39 billion$66.51 million17.16
Galapagos logo
GLPG
Galapagos
1.3$82.32+2.5%$5.38 billion$1.00 billion-12.47Analyst Report
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.9$111.68+4.7%$5.38 billionN/A-31.82Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$94.73+4.8%$5.05 billion$1.11 billion30.46Analyst Upgrade
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21+0.0%$4.75 billion$26.69 million-46.12
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$79.25+4.3%$4.75 billionN/A-6.46Earnings Announcement
Analyst Report
Insider Buying
Analyst Revision
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$76.17+10.5%$4.45 billion$6.87 million-7.36Analyst Report
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$129.86+0.4%$4.43 billion$26.52 million-11.44Earnings Announcement
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$73.26+4.8%$4.42 billion$806.43 million-10.38Analyst Report
High Trading Volume
News Coverage
Gap Up
IMAB
I-Mab
1.1$61.23+3.8%$4.41 billion$4.31 million-2.12Analyst Report
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$30.01+0.2%$4.37 billion$204.89 million-37.51News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$62.36+7.1%$4.32 billion$36.13 million-93.07Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.1$23.44+1.3%$4.27 billion$114.62 million-9.45Earnings Announcement
Analyst Report
Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$57.00+0.6%$4.01 billion$306.98 million-8.15Earnings Announcement
Analyst Revision
Insmed logo
INSM
Insmed
1.2$37.91+1.4%$3.91 billion$136.47 million-14.58Earnings Announcement
Analyst Report
Arvinas logo
ARVN
Arvinas
1.9$75.98+2.0%$3.68 billion$42.98 million-29.68Earnings Announcement
Analyst Downgrade
Insider Selling
Unusual Options Activity
Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.52+0.2%$3.66 billionN/A-6.13
LEGN
Legend Biotech
1.2$25.79+1.9%$3.40 billion$64.39 million0.00Increase in Short Interest
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$121.61+2.4%$3.29 billionN/A-60.50Earnings Announcement
Analyst Report
High Trading Volume
Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.4$24.75+2.7%$3.26 billion$80.43 million117.86News Coverage
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.